Welcome to LookChem.com Sign In|Join Free

CAS

  • or

196880-47-4

Post Buying Request

196880-47-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

196880-47-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 196880-47-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,8,8 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 196880-47:
(8*1)+(7*9)+(6*6)+(5*8)+(4*8)+(3*0)+(2*4)+(1*7)=194
194 % 10 = 4
So 196880-47-4 is a valid CAS Registry Number.

196880-47-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[[tert-butyl(diphenyl)silyl]oxymethyl]benzaldehyde

1.2 Other means of identification

Product number -
Other names 4-(tert-butyldiphenylsilanoxymethyl)benzaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:196880-47-4 SDS

196880-47-4Downstream Products

196880-47-4Relevant articles and documents

NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE

-

Paragraph 0585-0860, (2021/05/28)

PROBLEM TO BE SOLVED: To provide a compound that specifically activates an LPA4 receptor, and a pharmaceutical composition containing the same. SOLUTION: This invention relates to a novel lysophosphatidic acid derivative that has an agonistic action on an LPA4 receptor and is useful for the prevention and/or treatment of a disease with angiodysplasia caused by the LPA4 receptor, or a disease associated with angiopathy, or symptoms associated therewith. This invention also relates to a pharmaceutical composition containing the lysophosphatidic acid derivative. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

A new approach to tubacin

Hong, Jian,Xu, Xin,Das, Debasis,Yang, Pengyu,Chen, Shu-Hui,Li, Ge

scheme or table, p. 50 - 53 (2010/09/04)

Tubacin, histone deacetylases, allyl borane reaction, stereoselective ketal formation, solution phase synthesis, hydroxyamide synthesis.A new simple synthesis of tubacin is reported. It entails the formation of the syn-1,3-diol unit and its stereoselective ketalization with a functionalized benzaldehyde derivative.

Selective oxidation of benzylic alcohols and TBDMS ethers to carbonyl compounds with CrO3-H5IO6

Zhang, Suhong,Xu, Liang,Trudell, Mark L.

, p. 1757 - 1760 (2007/10/03)

Benzyl alcohols and benzyl TBDMS ethers were efficiently oxidized to the corresponding carbonyl compounds in high yield with periodic acid catalyzed by CrO3 at low temperature (-78°C). The oxidation procedure was highly functional group tolerant and very selective for the TBDMS group over the TBDPS group. Georg Thieme Verlag Stuttgart.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 196880-47-4